Page 34 - ஹார்ட் ஸ்காட் ரோடினோ நம்பிக்கையற்ற மேம்பாடுகள் நாடகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Merck to Acquire Rahul Kakkar-Led Pandion Therapeutics for $1.85 Billion Rahul Kakkar WATERTOWN, Mass.– Merck and Pandion Therapeutics, Inc. announced that the companies have entered into a definitive agreement, under which Merck, through a subsidiary, will acquire Pandion, a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, for $60 per share in cash. This represents an approximate total equity value of $1.85 billion. “This acquisition builds upon Merck’s strategy to identify and secure candidates with differentiated and potentially foundational characteristics,” Dr. Dean Y. Li, president, Merck Research Laboratories, said in a statement. “Pandion has applied its TALON technology to develop a robust pipeline of candidates designed to re-balance the immune response with potential applications across a wide array of autoimmune diseases.”

United statesRahul kakkarCovington burlingPandion therapeutics incMerck research laboratoriesMeagher flomCredit suisse securities united statesCenterview partnersPandion therapeuticsHart scott rodino antitrust improvements actSuisse securitiesஒன்றுபட்டது மாநிலங்களில்ராகுல் கக்கர்கோவிங்டன் பர்லிங்பாண்டியன் சிகிச்சை இன்க்மெர்க் ஆராய்ச்சி ஆய்வகங்கள்